News about Drug Discovery & Development

Vizuro and DCB Partner to Advance Drug Discovery Precision Medicine with Causal Generative AI

Vizuro LLC and the Development Center for Biotechnology (DCB) have signed an MoU to advance multimodal AI-driven drug discovery and precision medicine, fostering innovation in the biotechnology and pharmaceutical sectors.

Drug Discovery & Development | 27/12/2024 | By Manvi |  489

Axcelead DDP Signs Drug Discovery Service Deal with Astellas for Targeted Protein Degraders

Under the agreement, Axcelead DDP will support Astellas’ targeted protein degrader discovery utilizing DegLeadTM Platform and contribute to the generation of breakthrough new drug candidate compounds.

Drug Discovery & Development | 27/12/2024 | By Aishwarya |  369

Mankind Pharma, Innovent Biologics to Commercialize Sintilimab for Cancer Care

This strategic collaboration aims to address the critical challenges in cancer treatment and improve patient access to innovative therapeutic options in the region.

Drug Discovery & Development | 27/12/2024 | By Aishwarya |  470

Aadi Bioscience Signs Licensing Deal with WUXI and HANGZHOU DAC for Novel ADC Portfolio

Per the terms of the license agreement, Aadi is granted exclusive rights to certain patents and know-how pertaining to three preclinical ADC programs leveraging HANGZHOU DAC's CPT113 linker payload technology targeting each of Protein Tyrosine Kinase 7 (PTK7), Mucin-16 (MUC16) and Seizure Related 6 Homolog (SEZ6).

Drug Discovery & Development | 21/12/2024 | By Aishwarya |  1085

Nxera Pharma and Shionogi Launch QUVIVIQ in Japan

QUVIVIQ™ is an oral Dual Orexin Receptor Antagonist (DORA) for the treatment of insomnia that selectively binds to receptors of the wake-promoting neuropeptide orexin (OX1R and OX2R), inhibiting excessive wakefulness and facilitating the transition to sleep.

Drug Discovery & Development | 19/12/2024 | By Aishwarya |  462

Glenmark Introduces Lacosamide Oral Solution

Glenmark’s Lacosamide Oral Solution, 10 mg/mL is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat Oral Solution, 10 mg/mL of UCB, Inc.

Drug Discovery & Development | 16/12/2024 | By Aishwarya |  491

Valisure Partners with Picket Pharmaceuticals for Independent Certification of Injectable Drugs

Valisure and Picket Pharmaceuticals discovered their shared mission through their involvement in the End Drug Shortages Alliance (EDSA).

Drug Discovery & Development | 07/12/2024 | By Aishwarya |  233

Alembic Pharma Gets Tentative Approval for Olopatadine Hydrochloride Ophthalmic Solution

Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7 percent (OTC) has an estimated market size of USD 22 million for twelve months.

Drug Discovery & Development | 07/12/2024 | By Aishwarya |  499

Eugia Pharma Gets FDA Approval for Pazopanib Tablets

Aurobindo Pharma has announced that its wholly owned subsidiary company, Eugia Pharma Specialities, has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Pazopanib Tablets, 200 mg.

Drug Discovery & Development | 06/12/2024 | By Aishwarya |  394

KBI Biopharma Signs Manufacturing Contract with Alanis Therapeutics

As part of this collaborative agreement, KBI will oversee cell line development, process optimization, analytical and formulation development, and the manufacturing of Alanis’ pre-clinical antagonistic antibody (mAb).

Drug Discovery & Development | 04/12/2024 | By Aishwarya |  441